Could poop pills help fight breast cancer? new trial aims to find out

NCT ID NCT07292142

Not yet recruiting Disease control Sponsor: Jewish General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether fecal microbiota transplants (FMT) from healthy donors can safely be added to standard chemotherapy and immunotherapy for triple-negative breast cancer. About 125 patients will take part, first in an observation phase and then in a treatment phase. The goal is to see if changing the gut bacteria can help more tumors respond fully to treatment before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal microbiota transplantation (FMT) from healthy donors
What this could lead to: If it works, this could point toward a way to make standard breast cancer treatment more effective for patients whose tumors don't fully respond.
What could go wrong: This is a very early, small pilot study (Phase 1/2) focused on safety and feasibility, not yet on effectiveness. The approach may not improve outcomes and could cause side effects from the transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
London Health Sciences Center

London, Ontario, Canada
The Ottawa Hospital Cancer Centre

Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.